No cure, no pay: an acceptable way of financing fertility treatments?
Recently three cost-effectiveness studies in health care have been carried out with the explicit goal to support reimbursement policy. The authors of this article were the main researchers for one of these studies: a cost-effectiveness analysis on in vitro fertilization. After the most important conclusions of the study are summarized, possible and impossible regulatory options for IVF and for other fertility treatments are discussed. Finally, these options are related to the actual decisions that have been made since the end of this study.
D003362:Cost-Benefit Analysis; D005260:Female; D005307:Fertilization in Vitro; D006291:Health Policy / Q000191:economics*; D006761:Hospitals; D006801:Humans; D009426:Netherlands; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000458:organization & administration*; D012052:Reimbursement, Incentive / Q000458:organization & administration*; D013673:Technology Assessment, Biomedical / Q000191:economics*